Details for Patent: 10,858,341
✉ Email this page to a colleague
Which drugs does patent 10,858,341 protect, and when does it expire?
Patent 10,858,341 protects AZSTARYS and is included in one NDA.
This patent has seventeen patent family members in twelve countries.
Summary for Patent: 10,858,341
Title: | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Abstract: | The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. |
Inventor(s): | Mickle; Travis (Kissimmee, FL), Guenther; Sven (Coralville, IA), Chi; Guochen (Coralville, IA) |
Assignee: | KemPharm, Inc. (Celebration, FL) |
Application Number: | 16/793,923 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,858,341
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Commave Therap | AZSTARYS | dexmethylphenidate hydrochloride; serdexmethylphenidate chloride | CAPSULE;ORAL | 212994-001 | May 7, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE | ⤷ Try a Trial | ||||
Commave Therap | AZSTARYS | dexmethylphenidate hydrochloride; serdexmethylphenidate chloride | CAPSULE;ORAL | 212994-002 | May 7, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE | ⤷ Try a Trial | ||||
Commave Therap | AZSTARYS | dexmethylphenidate hydrochloride; serdexmethylphenidate chloride | CAPSULE;ORAL | 212994-003 | May 7, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,858,341
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2017371327 | ⤷ Try a Trial | |||
Australia | 2020239746 | ⤷ Try a Trial | |||
Brazil | 112019011640 | ⤷ Try a Trial | |||
Canada | 3046486 | ⤷ Try a Trial | |||
China | 110234636 | ⤷ Try a Trial | |||
European Patent Office | 3551619 | ⤷ Try a Trial | |||
Israel | 267172 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |